myriad_S_stacked.png
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium
December 09, 2024 16:05 ET | Myriad Genetics, Inc.
Myriad Genetics, Inc. announced it will present new data at the 2024 San Antonio Breast Cancer Symposium.
logo-horizontal-main.png
Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings
December 09, 2024 16:05 ET | OncoCyte Corporation
Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings – January 13-16, 2025, San Francisco, CA
GlobalNewsWire Fluence Logo_Square.png
Fluence Energy, Inc. Announces Convertible Notes Offering and Intention to Enter into Capped Call Transactions
December 09, 2024 16:01 ET | Fluence
ARLINGTON, Va., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Fluence Energy, Inc. (Nasdaq: FLNC) (“Fluence” or the “Company”), a global market leader delivering intelligent energy storage, operational...
LENSAR_4Color.jpg
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 09, 2024 16:01 ET | LENSAR, Inc.
ORLANDO, Fla., Dec. 09, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors...
HealthEquitylogo-purple 2020.jpg
HealthEquity Reports Third Quarter Ended October 31, 2024 Financial Results
December 09, 2024 16:01 ET | HealthEquity, Inc.
Highlights of the third quarter include: Revenue of $300.4 million, an increase of 21% compared to $249.2 million in Q3 FY24.Net income of $5.7 million, compared to $14.7 million in Q3 FY24, with...
protara_therapeutics@2x.png
Protara Announces Proposed Public Offering
December 09, 2024 16:01 ET | Protara Therapeutics
NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare...
Biomea-Fusion_Logo_RGB_rev2_Email.png
Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia
December 09, 2024 16:01 ET | Biomea Fusion, Inc.
Preliminary data supports BMF-500’s potential as a transformative therapy for patients with FLT3 mutated relapsed or refractory (R/R) acute leukemiaBMF-500 showed a favorable safety and tolerability...
chimerix_logo.jpg
Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End
December 09, 2024 16:01 ET | Chimerix, Inc.
Potential Approval in Q3 2025 in Recurrent H3 K27M-Mutant Diffuse Glioma Submission Plan Follows Productive and Collaborative Pre-NDA Interactions with FDA Company to Host Conference Call on...
Fate Therapeutics.jpg
Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus
December 09, 2024 16:01 ET | Fate Therapeutics, Inc.
All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and Sustained B-cell Depletion with Favorable Safety Profile First Patient to Reach...
MYR Group logo
MYR Group Inc. to Attend Goldman Sachs Energy, CleanTech & Utilities Conference in January
December 09, 2024 16:00 ET | MYR Group, Inc.
THORNTON, Colo., Dec. 09, 2024 (GLOBE NEWSWIRE) -- MYR Group Inc. (“MYR Group”) (NASDAQ: MYRG), a holding company of leading specialty contractors serving the electric utility infrastructure,...